Tevogen Bio (NASDAQ:TVGN) Stock Price Down 2.8% – Time to Sell?

Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) were down 2.8% during trading on Tuesday . The company traded as low as $0.3401 and last traded at $0.3491. Approximately 464,857 shares traded hands during trading, a decline of 68% from the average daily volume of 1,441,715 shares. The stock had previously closed at $0.3590.

Wall Street Analysts Forecast Growth

TVGN has been the subject of a number of research reports. D. Boral Capital reduced their price target on shares of Tevogen Bio from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, November 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tevogen Bio in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Tevogen Bio currently has an average rating of “Hold” and a consensus target price of $5.00.

Tevogen Bio Price Performance

The company has a market cap of $69.36 million, a price-to-earnings ratio of -1.84 and a beta of -0.79. The business’s 50-day simple moving average is $0.43 and its 200-day simple moving average is $0.76.

Tevogen Bio (NASDAQ:TVGN) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03.

Institutional Trading of Tevogen Bio

A hedge fund recently raised its stake in Tevogen Bio stock. Bridgeway Capital Management LLC lifted its stake in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) by 66.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 82,500 shares of the company’s stock after acquiring an additional 33,000 shares during the period. Bridgeway Capital Management LLC’s holdings in Tevogen Bio were worth $65,000 as of its most recent SEC filing.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.